Show an ad over header. AMP

I am the FIRST

Biden's big COVID challenge: Fading vaccines may demand boosters

The Biden administration is intensely scrutinizing coronavirus vaccines' effectiveness over time, facing the daunting task of timing booster shots right while still convincing the unvaccinated that getting the jab is worthwhile.

The bottom line: The vaccines still work incredibly well at protecting against severe disease and death, meaning the benefits of getting vaccinated are immense. But it's less clear how well they're working at preventing infection, which has huge public health implications with so many Americans still unvaccinated.


“I think everybody believes this wanes over time, the question is to what extent,” a senior Biden official said. “Nobody wants to be behind the eight-ball here. We want to catch it before there’s an issue, and that’s why there is very intense scrutiny.”

  • But getting the timing right won't be easy, especially without better data than we have now.
  • “By the time we have the data that efficacy is declining, we’re already behind,” said a person close to the administration. “A public health decision can be made on imperfect data. So are you waiting for a ton of breakthrough cases and a ton of death and disease before you boost everyone? That’s not a good idea.”

Where it stands: All of the vaccines continue to offer almost 100% protection against death, and extremely strong protection against serious illness. Those findings have stayed consistent across the whole world.

  • But a growing body of research shows that the vaccines are losing some potency against milder infections.
  • At an individual level, that’s not a huge deal. But on a population level, it has tremendous consequences, as the data also suggests that people with breakthrough cases can effectively transmit the virus.
  • More transmission means more disease among the unvaccinated, and more disease among the unvaccinated means — as we’re seeing play out in the South — increasingly overwhelmed health systems.
  • And, ultimately, the more the virus spreads, the more likely it is that new variants emerge.

Details: Specific numbers vary from study to study and country to country, but directionally, there seems to be a clear trend:

  • Preliminary findings from the Mayo Clinic, which have not yet been peer-reviewed, show that the Pfizer vaccine is preventing significantly fewer infections now than it was before the Delta variant became dominant in the U.S. The same study found a smaller drop in the Moderna vaccine’s efficacy.
  • The study has raised alarm bells within the Biden administration, as Axios reported yesterday.
  • Pfizer itself has saidit believes its vaccines are losing around six percentage points of efficacy every two months.
  • And research from Israel and the U.K. reached similar conclusions, and Moderna has also said it believes boosters will be necessary.

The big question: If the vaccines are losing some of their punch against mild infections now, will they eventually become less effective against severe disease?

  • "There’s very intense scrutiny on whether there is waning against hospitalization," the senior Biden official said.
  • That hasn’t happened yet — every study continues to show that vaccinated people have near-total protection from death and hospitalization.
  • But neither the administration nor vaccine manufacturers want to take any chances.
  • “There is decreased efficacy against asymptomatic infection. While there's uncertainty, with Delta, it appears to be more important,” the source said.

What’s next: There’s a relatively simple solution to this problem — booster shots. Pfizer and Moderna are already working on them, and Israel has had good results after beginning to offer additional doses to older citizens.

  • Third doses will be expensive, and critics say the U.S. shouldn’t be buying up third doses while so much of the world is waiting for its first.

Between the lines: The mounting evidence of waning efficacy adds new urgency to the U.S.’ debate about boosters, but that debate is hamstrung by a severe lack of clear data from the CDC.

  • Experts trying to parse how well the vaccines are performing are relying heavily on data from other countries, in part, because the CDC has released very little formal data about the U.S. experience in the months since Delta became dominant.
  • Even top administration officials can’t get the information they want, making it harder to assess when boosters will be needed, and for whom.

The bottom line: "The vaccines are still having a positive impact. But we're painting this train as it goes 180 miles an hour," said Michael Osterholm, director of the Center for Infectious Disease Research and Policy.

Why the startup world needs to ditch "unicorns" for "dragons"

When Aileen Lee originally coined the term "unicorn" in late 2013, she was describing the 39 "U.S.-based software companies started since 2003 and valued at over $1 billion by public or private market investors."

Flashback: It got redefined in early 2015 by yours truly and Erin Griffith, in a cover story for Fortune, as any privately-held startup valued at $1 billion or more. At the time, we counted 80 of them.

Keep reading... Show less

Scoop: Facebook's new moves to lower News Feed's political volume

Facebook plans to announce that it will de-emphasize political posts and current events content in the News Feed based on negative user feedback, Axios has learned. It also plans to expand tests to limit the amount of political content that people see in their News Feeds to more countries outside of the U.S.

Why it matters: The changes could reduce traffic to some news publishers, particularly companies that post a lot of political content.

Keep reading... Show less

Scoop: Amazon quietly getting into live audio business

Amazon is investing heavily in a new live audio feature that's similar to other live audio offerings like Clubhouse, Twitter Spaces and Spotify's new live audio platform, sources tell Axios.

Why it matters: As with Amazon's efforts in podcasting and music subscriptions, the company sees live audio as a way to bolster the types of content it can offer through its voice assistant, Alexa, and its smart speaker products.

Keep reading... Show less

Hurricane Ida exposes America's precarious energy infrastructure

The powerful hurricane that plunged New Orleans into darkness for what could be weeks is the latest sign that U.S. power systems are not ready for a warmer, more volatile world.

The big picture: “Our current infrastructure is not adequate when it comes to these kinds of weather extremes,” Joshua Rhodes, a University of Texas energy expert, tells Axios.

Keep reading... Show less

"We must go further": 70% of adults in European Union are fully vaccinated

About 70% of adults in the European Union are fully vaccinated against COVID-19, Ursula von der Leyen, the president of the European Commission, said Tuesday.

Why it matters: The milestone makes the E.U. one of the world's leaders in inoculations, after an initially lagging vaccine campaign, the New York Times notes.

Keep reading... Show less

What Elizabeth Holmes jurors will be asked ahead of fraud trial

Jury selection begins today in USA v. Elizabeth Holmes, with the actual jury trial to get underway on Sept. 8.

Why it matters: Theranos was the biggest fraud in Silicon Valley history, putting both hundreds of millions of dollars and thousands of patients' health at risk.

Keep reading... Show less

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories